Kisspeptin-10 is a short peptide (a chain of ten amino acids) that acts at the very top of the hormonal ladder governing fertility — on nerve cells in the hypothalamus, not on the testes or ovaries. Kisspeptin was discovered as the natural “starter” of that ladder: it is what tells the brain to send the impulse from which everything else follows. In humans it has been examined in a dozen or so small physiological studies: given intravenously, kisspeptin-10 raises the hormone LH within half an hour and speeds up its pulses in men, yet in women during one phase of the cycle it does nothing at all, and the natural hormone GnRH is roughly three times more potent. Kisspeptin-10 is not a medicine and has never been tested against a hard endpoint such as pregnancy or improved fertility. Below we set out exactly what was measured, and where the data stop.
What kisspeptin-10 is
Kisspeptins are a family of peptides produced from a single gene (KISS1). The body carries them in several lengths — 54, 14, 13 and 10 amino acids — and every one of them ends in an identical ten-amino-acid tail (d'Anglemont de Tassigny et al., 2017). That tail is kisspeptin-10, described as the shortest kisspeptin sequence with full intrinsic activity (George et al., 2011). The longest form, kisspeptin-54, is the same “key” with a longer handle — and, as it turned out, the handle matters.
How it works — three floors of one axis
Fertility is governed by a chain of three floors. At the top sits the hypothalamus: a group of nerve cells releases the hormone GnRH in pulses. One floor down sits the pituitary (a small gland at the base of the brain), which answers those pulses by releasing two hormones, LH and FSH. At the bottom are the gonads (testes or ovaries), which under LH and FSH make testosterone or oestradiol and the germ cells.
Kisspeptin acts on a “switch” (the KISS1R receptor) sitting on the nerve cells that release GnRH — that is, on the top floor. This is an important difference from other compounds used in this area: chorionic gonadotropin imitates LH and acts directly on the gonads, the lowest floor. Kisspeptin replaces none of the hormones below it; it only presses the switch at the top, and everything downstream then has to work by itself. If the pituitary or the gonads are not working, kisspeptin has nothing to set in motion.
Structure, stability and the brain barrier
A short molecule is cleared quickly from the blood. In a mouse study, kisspeptin-10 disappeared from the bloodstream with a half-life of about 4 minutes, while the longer kisspeptin-54 took about 32 minutes (d'Anglemont de Tassigny et al., 2017). The same study showed, however, that clearance alone does not explain the difference in effect: even repeated injections of kisspeptin-10 over an hour failed to reproduce the long LH rise produced by a single injection of kisspeptin-54. Furthermore, only kisspeptin-54 activated GnRH cells behind the blood–brain barrier, which the authors read as the longer form probably crossing that barrier while the shorter one largely does not. We found no published measurement of the half-life of kisspeptin-10 in humans, so the figure of “4 minutes” belongs to mice, not to people.
What was studied — cells and animals
Animal work served mainly to establish why two forms of the same hormone behave differently. One point where rodents and humans parted company is worth noting: in animals, pulsatile, interrupted kisspeptin action looked like a precondition for generating GnRH pulses, whereas in humans — as shown below — it turned out not to be required (Anderson and Millar, 2022). A good illustration of why a rodent paper must never be read as evidence in people.
Human data — men
The best-described group is healthy men. In the study by George et al. (2011) a single intravenous administration of kisspeptin-10 to healthy men raised serum LH from 4.1 ± 0.4 to 12.4 ± 1.7 IU/l after 30 minutes (n = 6). The response to a higher amount is instructive: a threefold larger dose produced a smaller, not a larger, response. During a 22.5-hour infusion LH rose from 5.4 ± 0.7 to 20.8 ± 4.9 IU/l and testosterone from 16.6 ± 2.4 to 24.0 ± 2.5 nmol/l (n = 4). At a lower infusion rate the authors saw what interested them most: LH pulse frequency rose from 0.7 ± 0.1 to 1.0 ± 0.2 per hour and the mass of a single secretory burst from 3.9 ± 0.4 to 12.8 ± 2.6 IU/l.
The same team repeated the experiment in five men with type 2 diabetes and low testosterone (George et al., 2013). Their LH rise after a single administration was comparable to the healthy group, and during an 11-hour infusion LH rose from 3.9 to 20.7 IU/l, testosterone from 8.5 ± 1.0 to 11.4 ± 0.9 nmol/l, and LH pulse frequency from 0.6 to 0.9 per hour. This is an exploratory study in five people — it shows that the hypothalamic signal can be forced in such men, but says nothing about the consequences of longer administration.
How does that compare with what medicine already has? A team at Imperial College London gave healthy men kisspeptin-10, kisspeptin-54 and GnRH in random order at matched molar doses (Jayasena et al., 2015). The area under the LH curve during the infusion was 10.81 ± 1.73 for kisspeptin-10, 14.43 ± 1.27 for kisspeptin-54 and 34.06 ± 5.18 for GnRH — that is, GnRH was roughly three times more potent than kisspeptin-10 (n = 5 per group).
Human data — in women the cycle phase decides
Here the result is the most revealing of all. In the study by Jayasena et al. (2011) kisspeptin-10 raised LH and FSH in men even at low doses, whereas in healthy women during the follicular phase of the cycle it did not change gonadotropin levels at all — not intravenously, not subcutaneously, not by infusion, even at doses many times higher than those effective in men. In the same women during the preovulatory phase, intravenous administration did raise LH and FSH. The response to this peptide is therefore not a property of the compound but a property of the hormonal state of the person receiving it.
Work from Massachusetts General Hospital confirms the pattern: eight healthy postmenopausal women received a 24-hour continuous kisspeptin infusion and proved resistant to it. Women taking oestradiol were resistant at first, but in them LH pulse amplitude grew in proportion to the oestradiol concentration and the duration of the infusion (Lippincott et al., 2017). Without the right hormonal background, pressing the switch at the top produces nothing below.
Does continuous administration shut the axis down
A popular claim holds that continuous exposure to kisspeptin “tires out” the GnRH cells and paradoxically suppresses the whole axis, as happens with continuous administration of GnRH analogues. In the human literature that picture has not held up in its simple form. The review by Anderson and Millar (2022) summarises series of studies in men and women and states two things: a continuous infusion of kisspeptin-10 at receptor-saturating concentrations increased LH pulse frequency, and over 22 hours of such an infusion no desensitisation was found. From this the authors conclude that pulsatile kisspeptin action on GnRH cells is not a precondition for generating GnRH pulses in humans.
The time scale does matter, though. In a randomised study published in 2026 (Yeung et al.) 15 healthy men received kisspeptin-10 subcutaneously. Short infusions raised LH, FSH and testosterone in proportion to the amount given. Under a continuous infusion lasting 5 days, testosterone stayed elevated but gonadotropin levels returned to control values. When the same peptide was given intermittently — 8 hours of infusion and 16 hours off — the gonadotropin rise held for 12 days (mean LH change: control −0.16 ± 0.19; day 1: +1.68 ± 0.25; day 12: +1.14 ± 0.33). After 12 days a single administration still raised gonadotropins, which the authors read as evidence that the receptor remained functional. The conclusion is not “receptor desensitisation” but a fading response under several days of continuous delivery — and a maintained response when the delivery has gaps in it.
Safety and the limits of the evidence
Every human study cited here is a small physiological study: between 4 and 15 participants per group, run by three centres (Imperial College London, Edinburgh and Massachusetts General Hospital). They measured hormone levels in blood, not clinical outcomes — there is no study showing that kisspeptin-10 improves fertility, raises pregnancy rates or lifts testosterone durably. No serious adverse events were reported in these studies, but with participant numbers this small and durations counted in days, an absence of signal is not evidence of safety. Kisspeptin-10 is not an approved medicine in any country. Nor did we find any study in which kisspeptin was given together with gonadotropins — claims about such combinations have no data behind them. We deliberately give no methods of use and no doses; the figures above describe what was done in studies and are not a recommendation.
The wider context — three different floors of one axis
Kisspeptin is a useful reference point for understanding how compounds acting on the reproductive axis differ. Kisspeptin presses the switch at the top (the hypothalamus). Chorionic gonadotropin (HCG) imitates LH and acts at the very bottom, directly on the gonads. Menotropin (HMG) supplies LH and FSH activity together, also from below. Three different floors mean three different sets of conditions under which something can work — and three completely different states of evidence: the gonadotropins have been medicines for decades, kisspeptin-10 is a research tool.
Summary
Kisspeptin-10 is the shortest active fragment of natural kisspeptin and acts on the hypothalamic cells that release GnRH. In men the human data are consistent: it raises LH, FSH and testosterone and speeds up LH pulses, though less potently than GnRH itself. In women it works only during part of the cycle, and after menopause without oestradiol it barely works at all. The hypothesis that continuous exposure suppresses the axis did not hold over 22 hours of infusion, but over 5 days of continuous infusion the gonadotropin response faded — a difference between hours and days, not between “works” and “does not work”. The entire human literature consists of small physiological studies without clinical endpoints, so the strength of evidence for any application has to be called weak, even though the physiology itself is solidly described.
Sources
- Yeung AC, Phylactou M, Koysombat K, et al. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. European Journal of Endocrinology. 2026;195(2):206–216. PMID: 42549827. DOI: 10.1093/ejendo/lvag134. pubmed.ncbi.nlm.nih.gov/42549827
- George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. The Journal of Clinical Endocrinology and Metabolism. 2011;96(8):E1228–E1236. PMID: 21632807. DOI: 10.1210/jc.2011-0089. pubmed.ncbi.nlm.nih.gov/21632807
- Jayasena CN, Abbara A, Narayanaswamy S, et al. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Human Reproduction. 2015;30(8):1934–1941. PMID: 26089302. DOI: 10.1093/humrep/dev143. pubmed.ncbi.nlm.nih.gov/26089302
- Jayasena CN, Nijher GM, Comninos AN, et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. The Journal of Clinical Endocrinology and Metabolism. 2011;96(12):E1963–E1972. PMID: 21976724. DOI: 10.1210/jc.2011-1408. pubmed.ncbi.nlm.nih.gov/21976724
- George JT, Veldhuis JD, Tena-Sempere M, Millar RP, Anderson RA. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clinical Endocrinology. 2013;79(1):100–104. PMID: 23153270. DOI: 10.1111/cen.12103. pubmed.ncbi.nlm.nih.gov/23153270
- Lippincott MF, Chan YM, Rivera Morales D, Seminara SB. Continuous Kisspeptin Administration in Postmenopausal Women: Impact of Estradiol on Luteinizing Hormone Secretion. The Journal of Clinical Endocrinology and Metabolism. 2017;102(6):2091–2099. PMID: 28368443. DOI: 10.1210/jc.2016-3952. pubmed.ncbi.nlm.nih.gov/28368443
- Anderson RA, Millar RP. The roles of kisspeptin and neurokinin B in GnRH pulse generation in humans, and their potential clinical application. Journal of Neuroendocrinology. 2022;34(5):e13081. PMID: 34962670. DOI: 10.1111/jne.13081. pubmed.ncbi.nlm.nih.gov/34962670
- d'Anglemont de Tassigny X, Jayasena CN, Murphy KG, Dhillo WS, Colledge WH. Mechanistic insights into the more potent effect of KP-54 compared to KP-10 in vivo. PLoS One. 2017;12(5):e0176821. PMID: 28464043. DOI: 10.1371/journal.pone.0176821. pubmed.ncbi.nlm.nih.gov/28464043
For in-vitro laboratory research only. It is not a human medicine and is not for treatment.